rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Madhavan Balachandran

Director

Company insider

Files Form 4 as: Director, uniQure; Director, Stevanato Group S.p.A; Director, Replimune Group; Director, Catalent; EVP, Operations, Amgen.

Every Form 4 they filed

In numbers

Trades disclosed
146
Buys
0
Sells
16
Bought
$0
Sold
$12.7M
Companies
5
Companies where not an officer
4
First trade
28 Jan 2013
Last trade
17 Jun 2026
Last filed
26 Jun 2026

Companies traded

Where they are an officer
AMGN AmgenOfficer · Biotechnology · last 4 May 20160 buys · 4 sells
Everywhere else they filed: board seats, 10% stakes, other companies
QURE uniQureDirector · Biotechnology · last 17 Jun 20260 buys · 11 sells
STVN Stevanato Group S.p.ADirector · Medical Devices · last 15 Jun 20260 buys · 1 sell
REPL Replimune GroupDirector · Biotechnology · last 1 Apr 20260 buys · 0 sells
CatalentDirector · last 27 Oct 20230 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
40Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Code M$168K5,295 at $31.71filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Code M$124K6,390 at $19.39filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$249K5,295 at $47.08filing
17 Jun 2026filed 22 Jun 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—5,295 at $0.00filing
17 Jun 2026filed 22 Jun 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—6,390 at $0.00filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$205K4,700 at $43.66filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$72K1,690 at $42.60filing
17 Jun 2026filed 22 Jun 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—5,295 at $0.00filing
17 Jun 2026filed 22 Jun 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—6,390 at $0.00filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Code M$168K5,295 at $31.71filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Code M$124K6,390 at $19.39filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$249K5,295 at $47.08filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$205K4,700 at $43.66filing
17 Jun 2026filed 22 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$72K1,690 at $42.60filing
15 Jun 2026filed 26 Jun 2026STVN Stevanato Group S.p.AMedical DevicesSEC FORM 4 Sold$26K1,493 at $17.09filing
15 Jun 2026filed 26 Jun 2026STVN Stevanato Group S.p.AMedical DevicesSEC FORM 4 Sold$26K1,493 at $17.09filing
15 Jun 2026filed 17 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Code M$85K10,000 at $8.49filing
15 Jun 2026filed 17 Jun 2026QURE uniQureBiotechnologySEC FORM 4 Sold$279K10,000 at $27.85filing
15 Jun 2026filed 17 Jun 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—10,000 at $0.00filing
15 Jun 2026filed 17 Jun 2026QURE uniQureoption or derivative · BiotechnologySEC FORM 4 Code M—10,000 at $0.00filing

Sectors

Health Care16

Buys in green, sells in red, by the company’s sector.

Related people

Rachna KhoslaSVP, Business Development · SVP, Business Development at Amgen, filing Form 4 there in the last year
Matthew C. BuschVP, Finance & CAO · VP, Finance & CAO at Amgen, filing Form 4 there in the last year
Omar IshrakDirector · Director at Amgen, filing Form 4 there in the last year
Michael Drake VDirector · Director at Amgen, filing Form 4 there in the last year
Charles M. HolleyDirector · Director at Amgen, filing Form 4 there in the last year
Mauro StocchiOfficer · Also traded STVN in the last 90 days
David J. TaylorRepresentative, OH-02 · Also traded AMGN in the last 90 days
Ro KhannaRepresentative, CA-17 · Also traded AMGN in the last 90 days